NASDAQ:INO has extended its slide on Wednesday as investors remain anxious about the FDA investigation into its vaccine candidate INO-4800 and the delivery device, CELLECTRA 2000. Inovio fell once again on Wednesday, shedding 4.55% to close the trading session at $10.50. As other biotech firms continue to inch closer to a successful vaccine candidate for the novel coronavirus, Inovio remains mired in an FDA inquiry with questions about its clinical trials.